Cells for bioartificial liver devices: The human hepatoma‐derived cell line C3A produces urea but does not detoxify ammonia

Extrahepatic bioartificial liver devices should provide an intact urea cycle to detoxify ammonia. The C3A cell line, a subclone of the hepatoma‐derived HepG2 cell line, is currently used in this context as it produces urea, and this has been assumed to be reflective of ammonia detoxification via a functional urea cycle. However, based on our previous findings of perturbed urea‐cycle function in the non‐urea producing HepG2 cell line, we hypothesized that the urea produced by C3A cells was via a urea cycle‐independent mechanism, namely, due to arginase II activity, and therefore would not detoxify ammonia. Urea was quantified using 15N‐ammonium chloride metabolic labelling with gas chromatography–mass spectrometry. Gene expression was determined by real‐time reverse transcriptase‐PCR, protein expression by western blotting, and functional activities with radiolabelling enzyme assays. Arginase inhibition studies used Nω‐hydroxy‐nor‐L‐arginine. Urea was detected in C3A conditioned medium; however, 15N‐ammonium chloride‐labelling indicated that 15N‐ammonia was not incorporated into 15N‐labelled urea. Further, gene expression of two urea cycle genes, ornithine transcarbamylase and arginase I, were completely absent. In contrast, arginase II mRNA and protein was expressed at high levels in C3A cells and was inhibited by Nω‐hydroxy‐nor‐L‐arginine, which prevented urea production, thereby indicating a urea cycle‐independent pathway. The urea cycle is non‐functional in C3A cells, and their urea production is solely due to the presence of arginase II, which therefore cannot provide ammonia detoxification in a bioartificial liver system. This emphasizes the continued requirement for developing a component capable of a full repertoire of liver function. Biotechnol. Bioeng. 2008;99: 644–651. © 2007 Wiley Periodicals, Inc.

[1]  S. Morris Enzymes of arginine metabolism. , 2004, The Journal of nutrition.

[2]  R Williams,et al.  Pilot‐controlled trial of the extracorporeal liver assist device in acute liver failure , 1996, Hepatology.

[3]  S. Morris,et al.  Expression, purification, and characterization of human type II arginase. , 2001, Archives of biochemistry and biophysics.

[4]  D. Rickman,et al.  Apc tumor suppressor gene is the "zonation-keeper" of mouse liver. , 2006, Developmental cell.

[5]  R. Chamuleau,et al.  Recent Developments on Human Cell Lines for the Bioartificial Liver , 2002, The International journal of artificial organs.

[6]  M. Takiguchi,et al.  Human liver-type arginase gene: structure of the gene and analysis of the promoter region. , 1988, Nucleic acids research.

[7]  Jyh-Ping Chen,et al.  Loofa Sponge as a Scaffold for the Culture of Human Hepatocyte Cell Line , 2003, Biotechnology progress.

[8]  M. Takiguchi,et al.  Molecular cloning and nucleotide sequence of cDNA for human liver arginase. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[9]  A. Demetriou,et al.  A Novel Plasma Filtration Therapy for Hepatic Failure: Preclinical Studies , 2006, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[10]  M. Takiguchi,et al.  Immunohistochemical Localization of Arginase II and Other Enzymes of Arginine Metabolism in Rat Kidney and Liver , 1998, The Histochemical Journal.

[11]  B. Davidson,et al.  A prospective study of isolated human hepatocyte function following liver resection for colorectal liver metastases: the effects of prior exposure to chemotherapy. , 2006, Journal of hepatology.

[12]  M. M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[13]  L. Alhonen,et al.  Genetic approaches to the cellular functions of polyamines in mammals. , 2004, European journal of biochemistry.

[14]  J. Vockley,et al.  Cloning and characterization of the human type II arginase gene. , 1996, Genomics.

[15]  W. Grody,et al.  Arginases I and II: do their functions overlap? , 2004, Molecular genetics and metabolism.

[16]  B. David,et al.  In Vitro Assessment of Encapsulated C3A Hepatocytes Functions in a Fluidized Bed Bioreactor , 2004, Biotechnology progress.

[17]  A. Weiner,et al.  Amino-terminal sequence analysis of proteins purified on a nanomole scale by gel electrophoresis. , 1972, The Journal of biological chemistry.

[18]  E. Gerner,et al.  Polyamines and cancer: old molecules, new understanding , 2004, Nature Reviews Cancer.

[19]  R. Butterworth Pathophysiology of Hepatic Encephalopathy: A New Look at Ammonia , 2002, Metabolic brain disease.

[20]  J. M. Fuentes,et al.  Immunological identity of the two different molecular mass constitutive subunits of liver arginase. , 1994, Biological chemistry Hoppe-Seyler.

[21]  S. Eaton,et al.  Ornithine transcarbamylase and arginase I deficiency are responsible for diminished urea cycle function in the human hepatoblastoma cell line HepG2. , 2007, The international journal of biochemistry & cell biology.

[22]  S. Morris,et al.  Human type II arginase: sequence analysis and tissue-specific expression. , 1997, Gene.

[23]  K. Onodera,et al.  Artificial liver support at present and in the future , 2006, Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs.

[24]  P. K. Smith,et al.  Measurement of protein using bicinchoninic acid. , 1985, Analytical biochemistry.

[25]  G. Darlington,et al.  Modulation of the liver specific phenotype in the human hepatoblastoma line Hep G2 , 1989, In Vitro Cellular & Developmental Biology.

[26]  A. Sheil,et al.  Comparison of porcine hepatocytes with human hepatoma (C3A) cells for use in a bioartificial liver support system. , 1998, Cell transplantation.

[27]  T. Gotoh,et al.  Chromosomal localization of the human arginase II gene and tissue distribution of its mRNA. , 1997, Biochemical and biophysical research communications.

[28]  T. Gotoh,et al.  Arginine metabolic enzymes, nitric oxide and infection. , 2004, The Journal of nutrition.

[29]  M. Strauss,et al.  Primary or established liver cells for a hybrid liver? Comparison of metabolic features. , 1995, ASAIO journal.

[30]  T. Matsumura,et al.  Development of a bioartificial liver with glutamine synthetase-transduced recombinant human hepatoblastoma cell line, HepG2. , 2000, Transplantation proceedings.

[31]  Guoyao Wu,et al.  Arginine metabolism: nitric oxide and beyond. , 1998, The Biochemical journal.

[32]  J. Kiley,et al.  Removal of Blood Ammonia by Hemodialysis.∗ , 1956, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[33]  R. Chamuleau,et al.  Which Are the Right Cells to be Used in a Bioartificial Liver? , 2005, Metabolic Brain Disease.

[34]  R. Chamuleau,et al.  Bioartificial Liver: Its Pros and Cons , 2006, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[35]  D. Ash Structure and function of arginases. , 2004, The Journal of nutrition.

[36]  Athanasios Mantalaris,et al.  Proliferation rates of HepG2 cells encapsulated in alginate are increased in a microgravity environment compared with static cultures. , 2005, Artificial organs.

[37]  D. Christianson,et al.  Arginase–boronic acid complex highlights a physiological role in erectile function , 1999, Nature Structural Biology.

[38]  M. Takiguchi,et al.  Molecular cloning of cDNA for nonhepatic mitochondrial arginase (arginase II) and comparison of its induction with nitric oxide synthase in a murine macrophage‐like cell line , 1996, FEBS letters.

[39]  M. Brosnan,et al.  A Mass Isotopomer Study of Urea and Glutamine Synthesis from 15N-labeled Ammonia in the Perfused Rat Liver* , 1996, The Journal of Biological Chemistry.

[40]  D. Ash,et al.  Classical and slow-binding inhibitors of human type II arginase. , 2001, Biochemistry.

[41]  J. Park,et al.  Ammonia Removal Using Hepatoma Cells in Mammalian Cell Cultures , 2000, Biotechnology progress.

[42]  P. Hayes,et al.  Improvement of C3A cell metabolism for usage in bioartificial liver support systems. , 2004, Journal of hepatology.

[43]  H. Conjeevaram,et al.  Initial experience with the modified extracorporeal liver-assist device for patients with fulminant hepatic failure: system modifications and clinical impact , 2002, Transplantation.

[44]  I. Marison,et al.  The importance of ammonia in mammalian cell culture. , 1996, Journal of biotechnology.

[45]  A. Moorman,et al.  Hepatocyte heterogeneity in the metabolism of amino acids and ammonia. , 1992, Enzyme.

[46]  J. Rozga Liver support technology – an update , 2006, Xenotransplantation.

[47]  C. Moinard,et al.  Polyamines: metabolism and implications in human diseases. , 2005, Clinical nutrition.